Literature DB >> 11920613

bc10: A novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer.

Irina Gromova1, Pavel Gromov, Julio E Celis.   

Abstract

To identify novel genes that may be associated with the invasive phenotype of bladder cancer, we compared the mRNA expression profiles of fresh noninvasive (grade II, Ta) and invasive (grade III, T2-T4) human transitional cell carcinomas (TCCs) by mRNA differential display. Using this approach, we isolated a novel gene, designated bc10 (bladder cancer, Mr 10 kDa) that was exclusively expressed in the noninvasive lesions as judged by reverse transcriptase polymerase chain reaction analysis of a panel of 30 grade II, Ta and grade III, T2-T4 TCCs. The full-length bc10 cDNA contains a complete open reading frame (ORF) of 263 bp and encodes a protein composed of 87 amino acids that has no homology to any of the known protein families. Transient expression of bc10 cDNA in COS1 cells yielded a primary translation product with an apparent Mr of 9.8 kDa and pI of 6.7, in agreement with the theoretical calculated value. Comparison of mouse and human bc10 genomic loci revealed an intronless organization of the coding region in both species as well as a highly conserved structure having 91% and 100% identity at the DNA (coding region) and protein levels, respectively. Southern analysis did not reveal gross DNA rearrangements within the bc10 genomic locus in the invasive tumors, implying that the differential expression of the gene most likely reflects alterations in messenger expression (transcription and/or mRNA decay). The downregulation of this novel marker in invasive tumors suggests a putative role in bladder cancer progression. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11920613     DOI: 10.1002/ijc.10244

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  An insight into the transcriptome of the digestive tract of the bloodsucking bug, Rhodnius prolixus.

Authors:  José M C Ribeiro; Fernando A Genta; Marcos H F Sorgine; Raquel Logullo; Rafael D Mesquita; Gabriela O Paiva-Silva; David Majerowicz; Marcelo Medeiros; Leonardo Koerich; Walter R Terra; Clélia Ferreira; André C Pimentel; Paulo M Bisch; Daniel C Leite; Michelle M P Diniz; João Lídio da S G V Junior; Manuela L Da Silva; Ricardo N Araujo; Ana Caroline P Gandara; Sébastien Brosson; Didier Salmon; Sabrina Bousbata; Natalia González-Caballero; Ariel Mariano Silber; Michele Alves-Bezerra; Katia C Gondim; Mário Alberto C Silva-Neto; Georgia C Atella; Helena Araujo; Felipe A Dias; Carla Polycarpo; Raquel J Vionette-Amaral; Patrícia Fampa; Ana Claudia A Melo; Aparecida S Tanaka; Carsten Balczun; José Henrique M Oliveira; Renata L S Gonçalves; Cristiano Lazoski; Rolando Rivera-Pomar; Luis Diambra; Günter A Schaub; Elói S Garcia; Patrícia Azambuja; Glória R C Braz; Pedro L Oliveira
Journal:  PLoS Negl Trop Dis       Date:  2014-01-09

2.  Overexpression of BLCAP induces S phase arrest and apoptosis independent of p53 and NF-kappaB in human tongue carcinoma : BLCAP overexpression induces S phase arrest and apoptosis.

Authors:  Jun Yao; Li Duan; Mingwen Fan; Jianhuan Yuan; Xinxing Wu
Journal:  Mol Cell Biochem       Date:  2006-10-10       Impact factor: 3.396

3.  Bladder cancer-associated protein is suppressed in human cervical tumors.

Authors:  Min Peng; Tingbo Xie; Juan Yu; Bin Xu; Qibin Song; Xinxing Wu
Journal:  Exp Ther Med       Date:  2011-12-05       Impact factor: 2.447

4.  Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.

Authors:  José M A Moreira; Gita Ohlsson; Pavel Gromov; Ronald Simon; Guido Sauter; Julio E Celis; Irina Gromova
Journal:  Mol Cell Proteomics       Date:  2009-09-25       Impact factor: 5.911

5.  Identification of genes up-regulated in urothelial tumors: the 67-kd laminin receptor and tumor-associated trypsin inhibitor.

Authors:  Christine P Diggle; Sheena Cruickshank; Jonathon D Olsburgh; Stephanie Pellegrin; Barbara Smith; Rosamonde E Banks; Peter J Selby; Margaret A Knowles; Jennifer Southgate; Patricia Harnden
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

6.  Specificity of ADAR-mediated RNA editing in newly identified targets.

Authors:  Eva M Riedmann; Sandy Schopoff; Jochen C Hartner; Michael F Jantsch
Journal:  RNA       Date:  2008-04-22       Impact factor: 4.942

7.  Altered adenosine-to-inosine RNA editing in human cancer.

Authors:  Nurit Paz; Erez Y Levanon; Ninette Amariglio; Amy B Heimberger; Zvi Ram; Shlomi Constantini; Zohar S Barbash; Konstantin Adamsky; Michal Safran; Avi Hirschberg; Meir Krupsky; Issachar Ben-Dov; Simona Cazacu; Tom Mikkelsen; Chaya Brodie; Eli Eisenberg; Gideon Rechavi
Journal:  Genome Res       Date:  2007-10-01       Impact factor: 9.043

8.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

9.  Immunoexpression analysis and prognostic value of BLCAP in breast cancer.

Authors:  Irina Gromova; Pavel Gromov; Niels Kroman; Vera Timmermans Wielenga; Ronald Simon; Guido Sauter; José M A Moreira
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Human BLCAP transcript: new editing events in normal and cancerous tissues.

Authors:  Federica Galeano; Anne Leroy; Claudia Rossetti; Irina Gromova; Philippe Gautier; Liam P Keegan; Luca Massimi; Concezio Di Rocco; Mary A O'Connell; Angela Gallo
Journal:  Int J Cancer       Date:  2010-07-01       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.